Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other immune cells bind anti-CD20 on coated B cells, which induces B cell deletion through a mechanism that is not clearly understood. In this issue of the Journal of Clinical Investigation, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B cells in live mice after treatment with anti-CD20 antibodies. Bousse and his group found that B cells circulating through the liver were the first ones depleted after treatment and that B cells in circulation were more susceptible to deletion than those stationary in the spleen or lymph nodes. The researchers used intravital two-photon microscopy to follow B cells in the liver as they halted near specialized Fc receptor-bearing cells called Kupffer cells. The Kupffer cells bound and consumed the anti-CD20-coated B cells. The study assigns a vital role to liver Kupffer cells in deleting B cells and describes techniques that may be used to improve the effectiveness of anti-CD20 therapy
TITLE: The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
Institut Pasteur, Paris, FRA
Phone: 33 1 45 68 85 51; Fax: ; E-mail: email@example.com
View this article at: http://www.jci.org/articles/view/70972?key=b0390c54a360d17753f4
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.